Naïve recirculating B cells mature simultaneously in the spleen and bone marrow

Running head: Contemporaneous maturation of B cells in BM and spleen

Annaiah Cariappa, Catharine Chase, Haoyuan Liu, Paul Russell, and Shiv Pillai

Massachusetts General Hospital and Harvard Medical School
Boston MA 02129, USA

Authors’ contributions: AC, conceptualized and designed research, performed research, collected data, analyzed data, and co-wrote the paper; CC, performed research; HL, performed research; PR, designed research; SP: conceptualized and designed research, and wrote the paper. All authors checked the final version of the manuscript.

Financial support: grants AI064930, CA102793, HL43340, and HL071932 from the National Institutes of Health, and a grant from the Roche Organ Transplantation Research Foundation.

Address correspondence to Dr. Shiv Pillai, MGH Cancer Center, Building 149, 13th Street, Charlestown Navy Yard, Boston, MA 02129; Telephone: 617-726-5619; Telefax: 617-724-9648; e-mail: pillai@helix.mgh.harvard.edu

Scientific heading: hematopoiesis

Keywords: B cells, cell differentiation, bone marrow, lymphotoxin alpha deficient mice
Abstract

We have recently demonstrated that IgD$^{hi}$ B cells can occupy an extravascular perisinusoidal niche in the bone marrow in addition to the well-established follicular niche in conventional secondary lymphoid organs. The spleen has long been considered to be the site at which newly formed B lymphocytes mature into IgD$^{hi}$ naïve recirculating B cells, but the existence of mutant mice that have selectively lost mature B cells in the bone marrow prompted an examination of B cell maturation at this latter site. Following a single pulse of BrdU in intact mice, sequential labeling of more mature B cell populations in the bone marrow suggested ongoing maturation at this site. Further evidence for B cell maturation in the bone marrow was obtained from analyses of transitional B cells in splenectomized lymphotoxin alpha deficient mice that lack all secondary lymphoid organs. In these mice, antibody secreting cells recognizing multivalent antigens were also observed in the bone marrow following an intravenous microbial challenge. These data suggest that newly formed B cells mature into IgD$^{hi}$ B cells simultaneously in the spleen and the bone marrow, and establish in a stringent manner that humoral immune responses can be initiated in situ in the bone marrow.
Introduction

Newly formed B cells emigrate from the bone marrow and home initially to the spleen where they mature via transitional stages primarily into long-lived follicular B cells, and where they also differentiate into marginal zone (MZ) B cells. Naïve follicular B cells express high levels of surface IgD and CD23, and have the ability to recirculate, entering and exiting follicular niches in secondary lymphoid organs in search of antigen. While mature B cells have long been described in the bone marrow, our recent studies suggest that the bone marrow may provide an alternative perisinusoidal niche for follicular phenotype IgD\textsuperscript{hi} B cells, wherein they have ready access to blood-borne pathogens and can thus contribute to T-independent IgM responses directed against such organisms. These studies describing bone marrow antibody-secreting cells generated in response to blood-borne pathogens were performed on splenectomized mice, but it remained formally possible that the IgM plasma cells in the bone marrow observed in these circumstances could have migrated to the bone marrow from some other secondary lymphoid organ.

Immature B cells in the bone marrow acquire the ability to migrate via the blood specifically to the spleen, presumably because these cells receive inhibitory signals that attenuate their ability to respond to chemokines and to thus home to lymph nodes or inflammatory sites. The unique architectural organization of the spleen is important for MZ B cell development and survival, and the evolutionary requirement for immature B cells to home to this organ may be linked to the need for such cells to differentiate into MZ B cells. However the teleological rationale for mature follicular B cell maturation to apparently occur only in the spleen, as is generally assumed to be the case, is unclear. It is reasonable to entertain the possibility that B
cell maturation might also occur in the bone marrow, particularly since immature B cells are
generated there, and since the perisinusoidal bone marrow niche does contain a large number of
B cells with an IgD\textsuperscript{hi} phenotype.\textsuperscript{12} Indeed, in splenectomized animals and humans, mature
follicular phenotype B cells are abundant in lymph nodes and in the perisinusoidal bone marrow
niche, and they presumably mature at some site distinct from the spleen, most likely within the
bone marrow compartment itself.

Another reason to explore the maturation of IgD\textsuperscript{hi} B cells in the bone marrow relates to
the poorly understood issue of the loss of these cells in certain mutant mice. Mice deficient in
Aiolos, CD22, and CD72 for instance, all lose mature B cells in the bone marrow but preserve
their phenotypic counterparts in other conventional secondary lymphoid organs.\textsuperscript{15-19} The above
null mice lack distinct negative regulators of the BCR. Mice lacking VCAM-1 also lack B cells
in the bone marrow,\textsuperscript{20,21} suggesting that VCAM-1 may contribute to entry into or retention
within this compartment. Although it has been suggested that CD22 might facilitate homing to
the bone marrow by recognizing \(\alpha_2,6\) linked sialic acid containing ligands on the endothelium,
\textsuperscript{22} this proposed mechanism seems unlikely to be important since B cells expressing mutant
CD22 that cannot bind \(\alpha_2,6\) linked sialic acid have been shown to home to the bone marrow as
efficiently as wild type B cells.\textsuperscript{23} A potential common link bringing together some of these
mutant mice is an enhancement in BCR signal strength, but why such an augmentation of
antigen receptor signaling may contribute to the loss of IgD\textsuperscript{hi} bone marrow B cells remains
unclear. In order to begin to explore the genetic regulation of mature B cell loss in the bone
marrow it is important to determine whether maturation of these cells might occur in this
compartment itself, since this maturation process, distinct from a parallel process occurring in
the spleen, could possibly be influenced by specific mutations. Genetic defects linked to
perisinusoidal B cell loss could therefore reflect defects in B cell maturation specifically in the bone marrow, represent defective homing of these cells to the bone marrow, or reflect aberrant and exaggerated egress of mature B cells from this site. A critical exploration of whether the maturation of IgD\textsuperscript{hi} B cells can normally occur in the bone marrow is clearly called for.
Materials and Methods

Mice

8-12 week old BALB/c, C57BL/6, and lymphotxin α deficient mice were obtained from Jackson Labs. Aly/aly mice\textsuperscript{24} were kindly made available by Dr. Gilles Benichou at MGH. Age and sex matched mice were used in all experiments. Animal procedures were cleared by the Subcommittee on Research Animal Care at MGH.

Continuous Bromodeoxyuridine (BrdU) labeling

Continuous labeling with BrdU (Sigma) was performed as described earlier.\textsuperscript{25} Briefly 0.25 mg/ml of BrdU and 2 mg/ml of glucose was administered in drinking water for 22 days, and the decay in labeling was followed for 4 weeks after cessation of BrdU administration. The BrdU decay data curves were generated by the least squares nonlinear regression analysis method using MacCurveFit 1.5 (Kevin Raner Software, Australia).

Pulse Bromodeoxyuridine (BrdU) labeling

Pulse labeling was achieved by administering a single intraperitoneal injection of BrdU (5 mg in one ml.), followed by the analysis of bone marrow and peripheral B cell populations.

Antibodies, staining and flow cytometry (FCM)

The following murine monoclonal antibody conjugates were used: Allophycocyanin (APC) and cy-chrome-RA3-6B2 (anti-CD45R/B220, rat IgG\textsubscript{2a}, κ, fluorescein isothiocyanate
(FITC)-DS-1 and R-PE-DS-1 (anti-IgM\textsuperscript{a} {Igh-6\textsuperscript{a}}, mouse IgG\textsubscript{1}, \textsuperscript{b}), R-PE/\textit{biotinylated} (BI)-R6-60.2 (anti-IgM, rat IgG\textsubscript{2a}), FITC/BI-AMS 9.1 (anti-IgD\textsuperscript{a} {Igh-5\textsuperscript{a}}, mouse IgG\textsubscript{2b}\textsuperscript{b}), BI/FITC-11-26c.2a (anti-IgD, rat IgG\textsubscript{2a}, \kappa), FITC-B44 (anti-BrdU, mouse IgG\textsubscript{1}, \kappa), FITC-AA4.1 (early B lineage antibody, rat IgG\textsubscript{2b}\kappa \textit{biotinylated} (BI)-J2 (anti-CD95, hamster IgG) and unlabelled 2.4G2 (anti-CD16/CD32 \{Fc\textsubscript{\gamma} III/II receptor\}, rat IgG\textsubscript{2b}, \kappa, culture supernatant) all from BD-Pharmingen; APC-AA4.1 (eBiosciences, San Diego, CA); R-PE-1B4B1 (anti-IgM, rat IgG) and BI-11-26 (anti-IgD, rat IgG\textsubscript{2a}, \kappa, all from Southern Biotech, Birmingham, Alabama); FITC-Peanut Agglutinin (PNA, Vector Labs, Burlingame, CA); \textit{biotinylated} antibodies were revealed by streptavidin-fluorochrome conjugates (also from BD-Pharmingen).

Flow cytometry was performed using standard methodology as described elsewhere.\textsuperscript{25,26} Intracellular staining to detect BrdU incorporated into DNA was performed as described earlier.\textsuperscript{25} Absolute number calculations were made as described before.\textsuperscript{12}

The cytometers used were: Epics Elite ESP and FC500 (both Coulter Corp.), MoFlo (DakoCytomation), and FACS\textit{Aria} and LSR II (both from Beckton, Dickinson, San Jose, CA). Gates in the spleen were set according to Hardy et al.,\textsuperscript{8} and Cariappa et al.,\textsuperscript{12} and the gates in the bone marrow were set according to Li et al.,\textsuperscript{27} Hendriks et al.,\textsuperscript{28} and Cariappa et al.\textsuperscript{12} Processed samples were analyzed using Epics Elite, and RXP (both from Beckman Coulter) and FloJo v8.1.1 (Treestar Inc.) analysis software.

\textbf{Bacterial challenge studies}
These were performed as described in an earlier study.\textsuperscript{12} Briefly, 0.5 \times 10^{6} bacteria derived from an overnight culture of \textit{S.typhimurium} strain SL3261\textsuperscript{29} were injected intravenously into mice housed in a BL2 facility.

\textbf{ELISPOT Assays}

ELISPOT assays were performed as described earlier\textsuperscript{12} using Salmonella flagellin (2.5\textgreek{ng}/ml, a kind gift from Dr. Bobby J. Cherayil at MGH), and lipopolysaccharide from \textit{Salmonella typhimurium} (LPS, 50\textgreek{ng}/ml, List Biological Laboratories, Campbell, CA).

\textbf{Statistical analyses}

P-values for differences between groups were determined by the Mann-Whitney U test using StatView version 5.0.1. For the BrdU decay data points, curves of best fit by the least squares method were generated using MacCurveFit 1.5 (Kevin Raner Software, Australia).
Results

Transitional B cells in the bone marrow

We have delineated B cell populations using IgM, IgD, and CD21 or by using these markers in combination with the AA4.1 antibody. We initially confirmed that newly formed/transitional type 1 (NF/T1) IgM$^{hi}$ IgD$^{lo/-}$ CD21$^{lo}$ B cells as well as IgM$^{hi}$ IgD$^{hi}$ CD23$^{hi}$ CD21$^{int}$ (F-II) and IgD$^{hi}$ IgM$^{lo}$ (F-I) follicular phenotype B cells are found both in the bone marrow as well as in the spleen (Figure 1A).\textsuperscript{6, 8, 10, 28, 30} Although immature B cells in the bone marrow are occasionally referred to as B220$^{lo}$ IgM$^{lo}$ B cells, we delineate Fraction E/immature B cells in the bone marrow, using criteria employed by Li et al.,\textsuperscript{27} and Hendriks et al.,\textsuperscript{28} as IgM$^+$ IgD$^-$ cells to distinguish them from IgM$^{hi}$ IgD$^{lo}$ NF/T1 cells. As seen in Figure 1B, in long term BrdU labeling and decay experiments, NF/T1 B cells have a slightly longer half-life than Fraction E B cells, supporting the view that these may represent distinct stages in a continuum of B cell development.

Some IgD$^{hi}$ CD23$^{hi}$ CD21$^{int}$ cells express relatively high levels of AA4.1 and are therefore also transitional B cells as defined using criteria established by Allman et al.,\textsuperscript{31} Although IgM$^{hi}$ IgD$^{hi}$ CD23$^{hi}$ CD21$^{hi}$ B cells, seen exclusively in the spleen, were also once categorized by some groups as transitional B cells, they are now widely recognized as specialized precursors of MZ B cells (MZP B cells).\textsuperscript{26, 32-34} The presence of similar spectral populations of B cells in the spleen and bone marrow, (with the exception of MZP and MZ B cells), suggested that IgD$^{hi}$ B cells may well mature in the bone marrow as well as in the spleen. We have previously established that IgD$^{hi}$ IgM$^{lo}$ mature follicular B cells in the spleen and bone marrow are equally long-lived.\textsuperscript{12}
Bone marrow and splenic B cells mature contemporaneously

To ask if mature bone marrow B cells are generated in situ contemporaneously with the maturation of B cells in the periphery, we injected mice with a single dose of BrdU which primarily labels cycling pro-B and pre-B cells in a transient manner, and dissipates extremely rapidly as these cells differentiate (data not shown). Further differentiation of these pulse-labeled cells was systematically followed by flow cytometric analysis of lymphocytes over an 8-day period in the bone marrow and the spleen (Figure 2A), as well as for 5 days in blood, lymph nodes, and peritoneum (Figure 2C). Our goal in these studies was to use a spike of BrdU incorporation in cycling cells as a marker to follow the short term in vivo differentiation of a cohort of pulse-labeled B cells. This approach was not designed to examine half-lives. Robust labeling of pro-B cells was noted in the bone marrow, and up to 50% of all pro-B cells (Table I and see below), and distinct peaks of bone marrow and splenic mature B cells were sequentially labeled following the pulse. Table I shows that a single pulse of BrdU effectively labeled a large proportion of cells in the bone marrow and this labeling approach appears to be a valid method for following a cohort of cells.

We observed a major peak of BrdU labeled immature IgM^+IgD^neg (Fraction E) cells in the bone marrow at day 2 (Table I). A smaller peak of IgM^hiIgD^lo (NF/T1) cells was also observed which peaked around the same day in the spleen and bone marrow (Figure 2A). Peaks of IgM^hiIgD^hi CD21^int (F-II) cells, and IgD^hiIgM^lo (F-I) cells, were observed later and contemporaneously in both the spleen and the bone marrow (Figure 2B). A decline in labeled cells is seen by day 5 in the bone marrow (Figure 2A and B), although more mature labeled cells persist in the spleen. This data suggests that newly generated B cells that have matured in the bone marrow may relatively rapidly egress this organ.
A major, albeit smaller, peak of BrdU labeled NF cells in the peripheral blood was seen on day 3 (Figure 2C, left panel) confirming that the peripheral circulation is a major conduit for the transport of newly formed B cells between the bone marrow and spleen. In contrast, the mesenteric lymph nodes and peritoneal fluid showed very few BrdU+ NF/T1 cells (Figure 2C, middle and right panels). Taken together, these results suggest that follicular B cell maturation may occur contemporaneously in the spleen and bone marrow, although maturation exclusively in the spleen and rapid homing to the bone marrow (or the converse scenario), cannot be excluded based solely on these results.

**Transitional B cell populations are generated in the bone marrow in the absence of the spleen and lymph nodes**

Though our BrdU studies confirmed that NF/T1 cells mainly travel from the bone marrow to the spleen, and not to lymph nodes (Figure 2), we recognized that it is formally possible that NF/T1 cells could perhaps mature in other peripheral lymphoid organs, and then return to the bone marrow. In order to more rigorously test this possibility, we studied two mutant mice that lack peripheral lymphoid tissue, lymphotoxin alpha (LTα) deficient and aly/aly animals. LTα/− mice lack lymph nodes and Peyer’s patches, and are known to be permissive for B cell maturation.36–38 We first established that BM B cell maturation was normal in the LTα/− mice. As seen in Figure 3, the examination of B cells using AA4.1 and CD21 as indicators of maturation revealed that B cells in mice lacking LTα matured in a fashion similar to that observed in their WT counterparts. In both wild type and LTα/− animals the levels of AA4.1, a cell surface marker of immature and transitional B cells,31 were highest in Fraction E followed by NF/T1 B cells and then IgDhiIgMhi (F-II) and IgDhiIgMlo (F-I) follicular phenotype B
cell populations (Figure 3, bottom row). These data supported the notion that the bone marrow contains transitional B cells and represents a distinct site of B cell maturation.

In order to establish that mature bone marrow B cells mature in situ and that the transitional B cells observed in the bone marrow do not represent cells that had migrated from the spleen, we splenectomized mutant mice, and examined B lineage cells in the bone marrow. We waited to perform analyses at least two weeks after splenectomy to ensure that transitional cells of recent splenic origin, which have a half-life of around 4 days, could be excluded as a source of any transitional B cells observed in the bone marrow. As can be seen in Figure 4A, AA4.1hi cells were abundant in the bone marrow of splenectomized LTα−/− animals both two and 15 days after surgery. Similar results were obtained with splenectomized wild type mice (data not shown). B cells mature in non-splenectomized and splenectomized LTα−/− mice in a similar fashion. These data indicate that the bone marrow supports in situ maturation in the complete absence of peripheral lymphoid tissue.

Aly/aly mice carry an inherited homozygous mutation in the NFκB inducing kinase (NIK) gene whose product is required for activating the alternate pathway of NFκB activation downstream of the lymphotoxin β receptor and the BAFF receptor. These mice lack lymph nodes and Peyer’s patches, and are known to be permissive for B cell maturation, albeit in a somewhat diminished fashion. We examined the bone marrow of aly/aly mice thirty days after removal of the spleen. As seen in Figure 4B, B cells mature in non-splenectomized and splenectomized aly/aly mice in a fashion similar to that observed in their heterozygous counterparts. Even though aly/aly mice have diminished B cell production, they nevertheless still generate transitional B cells in the bone marrow in the absence of the spleen. The presence
of continued B cell maturation in the absence of the spleen in both LTa− and aly/aly mice strongly supports the notion that the bone marrow represents a distinct site of B cell maturation.

**Intravenous challenge with Salmonella typhimurium induces activated bone marrow B cells in splenectomized LTA−/− deficient mice**

Collections of activated B220+ PNA+ Fas hi B cells are seen in the bone marrow of wild type mice within two days of an intravenous challenge with a blood borne microbe. These activated B cells may represent precursors of the antibody secreting cells seen in the bone marrow, or they might reflect abortive attempts to generate germinal centers in the bone marrow. As seen in Figure 5A, when splenectomized wild type mice or splenectomized LTA−/− mice were challenged intravenously with a vaccine strain of *Salmonella typhimurium* (SL3261), B220+PNA+Fas hi B cells were readily observed in the bone marrow. These data, obtained in the absence of all secondary lymphoid organs, indicate that activation of B cells in the bone marrow occurs *in situ*.

**IgM AFCs against surface antigens of SL3261 in mice that lack all secondary lymphoid organs**

Four days after intravenously challenging splenectomized wild type and LTA−/− mice with SL3261 cells, IgM ELISPOT assays were performed with bone marrow cells using LPS and purified flagellin from *Salmonella typhimurium* as antigens. As seen in Figure 5B, robust generation of antibody forming cells against Salmonella LPS and flagellin was observed in the bone marrows of mice lacking all secondary lymphoid organs. The reason for the heightened response in the LTA−/− mice, as compared with wild type mice is not known at present, but
presumably reflects the increase in bone marrow B cell numbers and consequently increased numbers of AFCs in these mutant mice which lack peripheral lymphoid tissue. These analyses complement our previous studies.\textsuperscript{12} They establish that antibody forming B cells that appear in the bone marrow following intravenous microbial challenge do not reflect the migration of activated B cells from other lymphoid organs to the bone marrow, but indeed represent the \textit{in situ} generation in this organ of IgM antibody forming cells against multivalent microbial antigens.
Discussion

These studies indicate that IgD$^{hi}$ B cells normally mature contemporaneously in the bone marrow and the spleen. They also formally establish that B cells in the bone marrow can be activated by blood borne microbes in the absence of all secondary lymphoid organs.

One approach that we used to examine B cell maturation in the bone marrow was the pulse labeling of cycling cells in this organ followed by the tracking of these labeled cells as they differentiate in vivo. The second approach was to use markers that are known to identify recently generated B cells and to examine differentiation in the bone marrow in wild type mice, in mice that lack most secondary lymphoid organs (but still retain the spleen), and in mice which lack all secondary lymphoid organs. BrdU pulse labeling was used as a cohort labeling tool in order to follow the post-mitotic differentiation of recently labeled pro-B and pre-B cells. It represents a very different technique from continuous labeling with BrdU, used generally to measure half-lives of B cell populations. Continuous labeling has clearly established that perisinusoidal bone marrow B cells are as long-lived as their counterparts in the spleen. Pulse labeling in a temporally circumscribed manner results in a fairly rapid dissipation of the BrdU marker, that has no bearing on half-lives of B cell populations. The pulse labeling of a cycling cohort, followed by a “chase” revealed the presence of a large pool of newly-formed B cells in the bone marrow in the blood, and, after a brief delay, in the spleen. At the early time points studied, emigration of newly formed B cell into the blood (presumably en route to the spleen) was detected. Labeled B cells in populations known to acquire recirculating ability (Fraction I and Fraction II follicular B cells) began to be observed in blood and the lymph nodes only at the end of the chase period. These results are consistent with the emigration of a large fraction of the
cells in the newly formed B cell pool from the bone marrow to the spleen, and the maturation of roughly equivalent numbers of B cells simultaneously in the spleen and bone marrow.

The original stathmokinetic studies on B cell maturation established that immature B cells emigrate to and mature in the spleen. Those studies did not simultaneously examine markers such as IgM and IgD that would have permitted the examination of maturation stages in the bone marrow as well. However the observation was made that recently labeled surface IgM B cells accumulate within the sinusoids of the bone marrow, and the speculative suggestion was made that B cells might mature in the bone marrow possibly in an intravascular location.

Recognizing that cohort labeling of cells, used in isolation, has its limitations, we chose to also examine B cell differentiation in the bone marrow in mice that retain the spleen, but which lack all other secondary lymphoid organs, as well as in mice that have been splenectomized and also lack all secondary lymphoid organs. These studies demonstrated the presence of transitional maturing B cell populations in the bone marrow, lending strong support to the results obtained from cohort studies.

Our current studies fill a long-standing lacuna in this field, and suggest that B cells mature in the bone marrow at the same time that they mature in the spleen. Given the functional relevance of perisinusoidal B cells in the bone marrow, these studies open the door to a more detailed analysis of the mechanisms that control the generation, retention, entry and emigration of mature B cells in the bone marrow.

One caveat of previous studies suggesting that bone marrow B cells may be activated by blood-borne pathogens was the failure to formally exclude the possibility that some B cell activation might occur in splenectomized wild type mice in lymph nodes and that this could be followed by the migration of these activated cells to the bone marrow. By analyzing
splenectomized \( LT\alpha^- \) mice that lack all secondary lymphoid organs we have stringently established that B cells in the perisinusoidal niche of the bone marrow can be activated \textit{in situ} and that these cells differentiate quite readily into antibody secreting cells \textit{in vivo}. These studies support the notion that the bone marrow is an important site for T-independent immune responses to blood-borne pathogens. Given that the humoral immune repertoire resides largely in IgD expressing B cells, IgM antibody generation in the bone marrow perisinusoidal niche may permit the harnessing of most of the B cell repertoire in responses to life threatening blood-borne pathogens.

\textbf{Acknowledgments:} Joanne Yetz-Aldape, Michelle Connole, John Daley, and Suzan Lazo-Kallanian, are thanked for help with flow cytometry.
References


20. Leuker CE, Labow M, Muller W, Wagner N. Neonatally induced inactivation of the vascular


22. Floyd H, Nitschke L, Crocker PR. A novel subset of murine B cells that expresses unmasked forms of CD22 is enriched in the bone marrow: implications for B-cell homing to the bone marrow. Immunology. 2000;101:342-347.


29. Hormaeche C, Mastroeni P, Harrison JA, de Hormaeche RD, Svenson S, Stockers BAD. Protection against oral challenge three months after i.v. immunization of BALB/c mice with live Aro *Salmonella typhimurium* and *Salmonella enteritidis* vaccines is serotype (species)-dependent and only partially determined by the main LPS O antigen. Vaccine. 1996;14:251-259.


43. Forster I, Rajewsky K. The bulk of the peripheral B-cell pool in mice is stable and not rapidly renewed from the bone marrow. Proc Natl Acad Sci U S A. 1990;87:4781-4784.
Table 1. BrdU pulse labelled cells in bone-marrow and spleen

<table>
<thead>
<tr>
<th>Fraction</th>
<th>Phenotype</th>
<th>% of BrdU+ cells in Fraction*</th>
<th>(day of peak labeling)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bone marrow</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A-D</td>
<td>CD45R+IgM+IgD-</td>
<td>50.0</td>
<td>1 day</td>
</tr>
<tr>
<td>E</td>
<td>IgM+IgD-</td>
<td>47.0</td>
<td>2 days</td>
</tr>
<tr>
<td>NF/T1</td>
<td>IgMhiIgDloCD21lo</td>
<td>38.2</td>
<td>2 days</td>
</tr>
<tr>
<td>F-II</td>
<td>IgDhiIgMhiCD21int</td>
<td>19.5</td>
<td>3 days</td>
</tr>
<tr>
<td>F-I</td>
<td>IgDhiIgMlo</td>
<td>7.5</td>
<td>3 days</td>
</tr>
<tr>
<td><strong>Spleen</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NF/T1</td>
<td>IgMhiIgDlo/-CD21lo</td>
<td>18.7</td>
<td>2 days</td>
</tr>
<tr>
<td>F-II</td>
<td>IgDhiIgMhiCD21int</td>
<td>6.2</td>
<td>3 days</td>
</tr>
<tr>
<td>F-I</td>
<td>IgDhiIgMlo</td>
<td>3.5 (5 days)</td>
<td></td>
</tr>
</tbody>
</table>

*See Figure 2A for absolute numbers in Fractions NF/T1, F-II and F-I. Number of mice examined as in legend for Figure 2.

#Most rapid influx on day 2. No statistical difference between days 2 and 3, see Figure 2A.
Legends to Figures

Figure 1. Categorization of B cells in the bone marrow and spleen.

(A) B cell populations in the bone marrow and spleen analyzed on the basis of surface IgM and IgD expression. Categorizations depend on analysis of CD21 expression as well (see Fig. 4A for CD21 levels in the BM). F-I refers to IgD\textsuperscript{hi}IgM\textsuperscript{lo}CD21\textsuperscript{int} follicular B cells and F-II to IgD\textsuperscript{hi}IgM\textsuperscript{hi}CD21\textsuperscript{int} follicular B cells. NF/T1 refers to IgM\textsuperscript{hi}IgD\textsuperscript{lo}CD21\textsuperscript{lo} B cells in the bone marrow and IgM\textsuperscript{hi}IgD\textsuperscript{lo/-}CD21\textsuperscript{lo} B cells in the spleen. Fraction E refers to IgM\textsuperscript{+}IgD\textsuperscript{−} B cells in the bone marrow. MZP B cells are IgM\textsuperscript{hi}IgD\textsuperscript{hi}CD21\textsuperscript{hi} presumed MZ precursors, and MZ B cells are IgM\textsuperscript{hi}IgD\textsuperscript{lo/-}CD21\textsuperscript{hi} B cells both of which are present only in the spleen (see refs. 8, 12, 27, 28 for gating strategy).

(B) Regression analysis of BrdU decay data (from a continuous labeling experiment) reveals that NF/T1 B cells and Fraction E B cells have distinct half-lives.

Figure 2. B cell differentiation in the bone marrow and spleen revealed by pulse labeling with BrdU of the pro-B/pre-B population.

(A) A contemporaneous and wave-like progression of BrdU labeled B cells was observed in the bone marrow and spleen.

(B) Representative flow cytometric histograms following BrdU labeling in splenic and bone marrow B cell fractions at various time points.

For the 2 day time point n= 7 mice. All other time points include results from 4 mice. Error bars represent ± SEM.
(C) BrdU⁺ NF/T1 B cells are readily observed in the peripheral blood (left panel), but minimally in lymph nodes (center) or the peritoneal cavity (right).

Figure 3. Transitional B cells are observed in the bone marrow of wild type and LTα⁻/⁻ mice.

B cell maturation in the bone marrow proceeds normally in the lymphotoxin alpha (LTα) deficient mouse as revealed using antibodies to IgM, IgD, and CD21. Comparison of the expression of AA4.1, a marker of recent B cell generation, revealed similar numbers of transitional cells in the bone marrow in wild type and LTα null mice. A representative experiment is shown.

n= 3 mice in each group. WT refers to wild type.

Figure 4. The spleen and other peripheral organs are not required for the maturation of B cells in the bone marrow.

(A) B cell maturation proceeds normally in the bone marrow in splenectomized lymphotoxin alpha deficient mice (lacking all secondary lymphoid organs). Bone marrow B cells were analyzed for AA4.1 expression two and 15 days after splenectomy. Recently generated AA4.1⁺ B cell populations were observed after splenectomy, and were comparable to those in non-splenectomized LTα⁺ mice, although overall B cell production was enhanced after splenectomy. A representative experiment is shown.

n= 3 mice in each group.
(B) B cell maturation proceeds normally in the bone marrow in splenectomized \textit{aly/aly} mice. Bone marrow B cells of \textit{aly/aly} mice were analyzed for AA4.1 expression thirty days after splenectomy. Recently generated AA 4.1\textsuperscript{hi} B cell populations were observed in these mice even after splenectomy, and are comparable to those in \textit{aly/+} mice. A representative experiment is shown.

\textit{n=3} mice per group.

\textbf{Figure 5.} Bone marrow perisinusoidal B cells respond to multivalent antigens in an antigen specific manner in the complete absence of lymphoid organs.

A. Analysis of CD95\textsuperscript{+}PNA\textsuperscript{+}CD45R\textsuperscript{+} B cells in the bone marrow of splenectomized wild type and \textit{LT\alpha\textsuperscript{–/–}} mice. Sham mice were injected with saline while Test mice were injected with SL3261 bacteria. The plots shown are representative of three mice in each group.

B. ELISPOT assay for IgM antibody forming cells in the bone marrow against LPS and flagella antigen in splenectomized wild type (C57BL/6) and \textit{LT\alpha\textsuperscript{–/–}} mice previously challenged intravenously with SL3261 bacteria. \textit{UI} denotes mice that were not challenged, and \textit{I} represents mice that received an intravenous challenge.
Figure 1.

A  Lymphocyte gate

BM

F-I

F-II

NF/T1

F-E

IgD

Spleen

F-I

F-II

NF/T1

F-E

IgM

B  Bone marrow

% BrdU+

Weeks post BrdU

NF/T1

F-E
Figure 2.

A

Bone marrow

Spleen

B

NF/T1

F-II

F-I

Control

2 hours

18 hours

Day 2

Day 3

Day 5

Day 8

Relative cell number

BrdU

B

Peripheral blood

Mesenteric lymph nodes

Peritoneal fluid

C

BrdU

(days in total organ)

Days

BrdU

(days in total organ)

Days

BrdU

(days in total organ)

Days
Figure 3.

Bone marrow
Lymphoid gate

WT

<table>
<thead>
<tr>
<th>IgD</th>
<th>IgM</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.9</td>
<td>0.9</td>
</tr>
<tr>
<td>5.3</td>
<td>1.5</td>
</tr>
</tbody>
</table>

LTα−/−

<table>
<thead>
<tr>
<th>NF/T1</th>
<th>F-II</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.9</td>
<td>0.8</td>
</tr>
<tr>
<td>5.8</td>
<td>1.6</td>
</tr>
</tbody>
</table>

WT

% of maximum

CD21

<table>
<thead>
<tr>
<th>F-E</th>
<th>NF/T1</th>
<th>F-II</th>
<th>F-I</th>
</tr>
</thead>
</table>

LTα−/−

% of maximum

AA4.1

<table>
<thead>
<tr>
<th>F-E</th>
<th>NF/T1</th>
<th>F-II</th>
<th>F-I</th>
</tr>
</thead>
</table>
Figure 4.

A

Bone marrow
Lymphoid gate
LTα^−/−

Non-splen.

<table>
<thead>
<tr>
<th>Strain</th>
<th>E</th>
<th>NF/T1</th>
<th>F-II</th>
<th>F-I</th>
</tr>
</thead>
<tbody>
<tr>
<td>LTα^−/− (Non-splen.)</td>
<td>4.4 (0.4)</td>
<td>2.8 (0.1)</td>
<td>17.4 (1.2)</td>
<td>15.2 (0.9)</td>
</tr>
<tr>
<td>LTα^−/− (15 d post-splen.)</td>
<td>7.5 (1.1)</td>
<td>5.3 (0.7)</td>
<td>19.3 (0.9)</td>
<td>16.3 (0.6)</td>
</tr>
</tbody>
</table>

B

Bone marrow

alv/+  
alv/alv

Non-splen.

<table>
<thead>
<tr>
<th>Strain</th>
<th>E</th>
<th>NF/T1</th>
<th>F-II</th>
<th>F-I</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-splen.</td>
<td>1.6</td>
<td>0.2</td>
<td>0.3</td>
<td>0.92</td>
</tr>
<tr>
<td>30 d post-splen.</td>
<td>1.4</td>
<td>0.47</td>
<td>1.1</td>
<td>1.6</td>
</tr>
</tbody>
</table>
Figure 5.

A

Day 3 post inj. and splenectomy

Bone marrow

CD45R<sup>+</sup> gate

WT

Sham 1.0  Test 19.6

LTα<sup>-/-</sup>

Sham 0.6  Test 14.0

CD95

PNA

B

Salmonella specific IgM antibody forming cells in BM

(absolote number in total organ)

ELISPOT ag:

<table>
<thead>
<tr>
<th></th>
<th>LPS</th>
<th>Flagella ag.</th>
</tr>
</thead>
<tbody>
<tr>
<td>C57BL/6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LTα&lt;sup&gt;-/-&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Day 4 post splenectomy and immunization
Naive recirculating B cells mature simultaneously in the spleen and bone marrow

Annaiah Cariappa, Catharine Chase, Haoyuan Liu, Paul Russell and Shiv Pillai